Inhibitor compounds of phosphodiesterase type 10A

US9200005B2 · kind B2 · utility

Assignees

• Abb Vie Deutschland Gmbh & Co. KG · DE
• Abb Vie Inc. · US

Inventors

• Katja Jantos · Ludwigshafen, DE
• Michael Ochse · Wiesbaden, DE
• Hervé Geneste · Schifferstadt, DE
• Jayne Froggett · Speyer, DE
• Clarissa Jakob · North Chicago, US
• Karla Drescher · Ludwigshafen, DE
• Jurgen Dinges · Wadsworth, US

Key dates

• Filing date: Feb 25, 2014
• Grant date: Dec 1, 2015
• Expiry date: Feb 25, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof:In formula I the variables X1 is CH or N, X2 is O or S and where R1, R2, R3, R4 and Q are as defined in the claims.The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.